Pfizer (NYSE:PFE) Shares Up 1.2% – Time to Buy?

Pfizer Inc. (NYSE:PFE)’s stock price rose 1.2% during trading on Monday . The company traded as high as $24.72 and last traded at $24.4610. Approximately 42,686,866 shares traded hands during mid-day trading, an increase of 0% from the average daily volume of 42,519,129 shares. The stock had previously closed at $24.17.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer was mentioned as a potential beneficiary after Ionis Pharmaceuticals’ Wainua Phase 3 failure, which may have improved relative sentiment toward Pfizer and other competitors in the biotech space. The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions (PFE)
• Neutral Sentiment: Analysts continue to view Pfizer as a value stock, but recent commentary suggests the shares may be cheap for a reason, keeping investor enthusiasm in check. 2 Value Stocks Worth Your Attention and 1 Facing Headwinds
• Neutral Sentiment: BMO Capital Markets cut its price target on Pfizer to $30 from $34 while keeping an outperform rating, signaling slightly softer expectations but still implying upside from current levels. Benzinga analyst update on Pfizer
• Neutral Sentiment: Guggenheim also lowered its target on Pfizer to $35 from $36, though it maintained a buy rating, reinforcing a generally cautious but still constructive analyst stance. Street Insider analyst update on Pfizer
• Neutral Sentiment: Broader analyst coverage remains mixed, with Pfizer receiving an average “hold” rating, which helps explain why the stock has not attracted stronger momentum. Pfizer Inc. Receives Average Rating of Hold from Analysts
• Negative Sentiment: Multiple firms trimmed their price targets on Pfizer, suggesting analysts are dialing back expectations for near-term performance. Benzinga analyst update on Pfizer

Analyst Ratings Changes

PFE has been the topic of a number of research reports. Wall Street Zen downgraded Pfizer from a “buy” rating to a “hold” rating in a research note on Saturday, July 4th. Royal Bank Of Canada raised Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 target price on the stock in a report on Tuesday, June 9th. HSBC cut Pfizer from a “buy” rating to a “hold” rating and dropped their target price for the stock from $32.00 to $28.00 in a research report on Monday, July 6th. Morgan Stanley upped their price target on shares of Pfizer from $27.00 to $28.00 and gave the company an “equal weight” rating in a research report on Friday, April 10th. Finally, JPMorgan Chase & Co. lowered their price objective on shares of Pfizer from $30.00 to $28.00 and set a “neutral” rating on the stock in a research note on Wednesday, July 8th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $28.50.

Pfizer Trading Up 1.2%

The stock has a 50 day moving average of $25.37 and a 200-day moving average of $26.19. The company has a market capitalization of $139.41 billion, a P/E ratio of 18.67 and a beta of 0.35. The company has a current ratio of 1.25, a quick ratio of 0.94 and a debt-to-equity ratio of 0.67.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.72 by $0.03. The business had revenue of $14.45 billion for the quarter, compared to the consensus estimate of $13.84 billion. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The company’s revenue for the quarter was up 5.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.92 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, research analysts predict that Pfizer Inc. will post 2.96 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 7.0%. The ex-dividend date of this dividend is Friday, July 24th. Pfizer’s dividend payout ratio (DPR) is 131.30%.

Institutional Investors Weigh In On Pfizer

Institutional investors and hedge funds have recently modified their holdings of the stock. Vermillion Wealth Management Inc. increased its holdings in Pfizer by 19.4% in the 1st quarter. Vermillion Wealth Management Inc. now owns 2,352 shares of the biopharmaceutical company’s stock valued at $66,000 after acquiring an additional 382 shares during the last quarter. Triad Wealth Partners LLC increased its holdings in shares of Pfizer by 1.9% in the fourth quarter. Triad Wealth Partners LLC now owns 20,466 shares of the biopharmaceutical company’s stock worth $510,000 after purchasing an additional 386 shares during the last quarter. Eagle Capital Management LLC lifted its position in shares of Pfizer by 0.3% in the first quarter. Eagle Capital Management LLC now owns 126,573 shares of the biopharmaceutical company’s stock worth $3,554,000 after buying an additional 390 shares in the last quarter. ETF Store Inc. boosted its stake in Pfizer by 3.8% during the fourth quarter. ETF Store Inc. now owns 10,913 shares of the biopharmaceutical company’s stock valued at $272,000 after buying an additional 396 shares during the last quarter. Finally, Delta Financial Advisors LLC boosted its stake in Pfizer by 1.6% during the first quarter. Delta Financial Advisors LLC now owns 25,266 shares of the biopharmaceutical company’s stock valued at $709,000 after buying an additional 398 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.